|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.150 USD | -0.77% |
|
+1.18% | +22.04% |
| Nov. 06 | Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q3 Revenue $47.7M | MT |
| Nov. 06 | Vanda Pharmaceuticals Inc., Q3 2024 Earnings Call, Nov 06, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 300M 285M 265M 236M 421M 25.4B 461M 3.28B 1.22B 10.42B 1.13B 1.1B 45.19B | P/E ratio 2024 * |
-16.3x | P/E ratio 2025 * | 137x |
|---|---|---|---|---|---|
| Enterprise value | 111M 106M 98.22M 87.67M 156M 9.42B 171M 1.22B 453M 3.86B 418M 409M 16.76B | EV / Sales 2024 * |
0.56x | EV / Sales 2025 * | 1.34x |
| Free-Float |
96.85% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Vanda Pharmaceuticals Inc.
More recommendations
More press releases
More news
| 1 day | -0.77% | ||
| 1 week | +1.18% | ||
| 1 month | +10.52% | ||
| 3 months | -2.65% | ||
| 6 months | +0.78% | ||
| Current year | +22.04% |
1 week
4.88
5.42
1 month
4.655.55
Current year
3.466.75
1 year
3.466.75
3 years
3.3018.00
5 years
3.3021.86
10 years
3.3033.44
| Director | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 2003-04-30 | |
Kevin Moran
DFI | Director of Finance/CFO | 40 | 2020-03-14 |
Scott Howell
HRO | Human Resources Officer | - | 2019-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chairman | 64 | - | |
Richard Dugan
BRD | Director/Board Member | 82 | 2005-11-30 |
Phaedra Chrousos
BRD | Director/Board Member | 44 | 2019-04-23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.34% | 28 M€ | +14.26% | ||
| 0.22% | 26 M€ | +10.51% | - | |
| 0.05% | 0 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.77% | +1.18% | +32.05% | -67.71% | 300M | ||
| +0.77% | +3.81% | +33.31% | +128.36% | 121B | ||
| -0.62% | +1.66% | -7.93% | +18.97% | 80.72B | ||
| -0.74% | +0.65% | +40.52% | +134.65% | 37.35B | ||
| -1.93% | +4.65% | +19.10% | -64.60% | 28.38B | ||
| +4.29% | +12.85% | +14.67% | -38.92% | 22.84B | ||
| +1.50% | +1.03% | -39.59% | -65.73% | 19.65B | ||
| +0.99% | +2.86% | -29.29% | -40.32% | 13.72B | ||
| -2.53% | -2.84% | +766.67% | +276.73% | 13.61B | ||
| -0.95% | +2.75% | +183.41% | +181.60% | 13.45B | ||
| Average | +0.00% | +2.97% | +101.29% | +46.30% | 35.06B | |
| Weighted average by Cap. | +0.15% | +3.20% | +49.91% | +67.48% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 198M 188M 175M 156M 278M 16.76B 304M 2.16B 806M 6.88B 745M 728M 29.83B | 272M 258M 240M 214M 381M 22.99B 417M 2.97B 1.1B 9.43B 1.02B 998M 40.9B |
| Net income | -18.72M -17.74M -16.51M -14.73M -26.23M -1.58B -28.75M -204M -76.11M -649M -70.33M -68.77M -2.82B | 4.57M 4.33M 4.03M 3.6M 6.4M 386M 7.01M 49.87M 18.57M 158M 17.16M 16.78M 687M |
| Net Debt | -189M -179M -167M -149M -265M -15.98B -290M -2.06B -768M -6.55B -710M -694M -28.43B | 65.1M 61.7M 57.41M 51.24M 91.21M 5.51B 99.96M 711M 265M 2.26B 245M 239M 9.8B |
More financial data
* Estimated data
Employees
203
Calendar
2025-02-04
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-11-29 | 5.150 $ | -0.77% | 264,859 |
| 24-11-27 | 5.190 $ | +4.22% | 833,924 |
| 24-11-26 | 4.980 $ | -1.39% | 529,323 |
| 24-11-25 | 5.050 $ | -0.79% | 487,097 |
Delayed Quote Nasdaq, November 29, 2024 at 01:00 pm EST
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
5.150USD
Average target price
10.43USD
Spread / Average Target
+102.48%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- VNDA Stock